ATIC
ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase, also known as PURH, AICARFT and IMPCHASE) is a bifunctional enzyme that catalyses the last two steps of purine biosynthesis. It is a member of the PurH family and belongs to the purinosome gene group. Browse Assay Genie's current range of ATIC research reagents below, or read on for the biology behind the target.
ATIC carries out the final two reactions of the de novo purine biosynthetic pathway. It first acts as a transformylase, incorporating a formyl group into the AMP analogue AICAR (5-amino-1-(5-phospho-beta-D-ribosyl)imidazole-4-carboxamide) to produce the intermediate formyl-AICAR (FAICAR). Either 10-formyldihydrofolate or 10-formyltetrahydrofolate can serve as the formyl donor. The enzyme then catalyses cyclisation of FAICAR to inosine monophosphate (IMP).
The two activities sit in separate domains of a single polypeptide. The N-terminal domain has phosphoribosylaminoimidazolecarboxamide formyltransferase activity, and the C-terminal domain has IMP cyclohydrolase activity. The protein localises to the cytosol, and the human gene encoding it is annotated as ATIC. The mouse and rat orthologues are both named Atic, which allows comparative work in rodent models. HGNC places the gene in the purinosome group.
ATIC is also able to convert thio-AICAR to 6-mercaptopurine ribonucleotide, an inhibitor of purine biosynthesis used in the treatment of human leukaemias, which makes it relevant to studies of antimetabolite pharmacology. UniProt additionally reports that the protein promotes insulin receptor (INSR) autophosphorylation and is involved in INSR internalisation. A mutation in the ATIC gene results in AICA-ribosiduria. Researchers studying the ATIC protein commonly use an ATIC antibody or ATIC ELISA kit to examine its expression in different experimental systems.
ATIC catalyses the last two steps of de novo purine biosynthesis, converting AICAR to formyl-AICAR and then to inosine monophosphate.
HGNC classifies ATIC in the purinosome gene group, making it a relevant protein for studying how purine biosynthetic enzymes are organised.
ATIC can convert thio-AICAR to 6-mercaptopurine ribonucleotide, an inhibitor of purine biosynthesis used to treat human leukaemias.
ATIC promotes insulin receptor autophosphorylation and is involved in INSR internalisation, linking purine metabolism to insulin signalling research.
ATIC is a bifunctional enzyme that catalyses the last two steps of purine biosynthesis. Its transformylase activity converts AICAR to formyl-AICAR, and its cyclohydrolase activity then cyclises formyl-AICAR to inosine monophosphate (IMP). It is found in the cytosol.
ATIC is also known as PURH, AICARFT and IMPCHASE. The HGNC full name is 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase, and UniProt lists it as bifunctional purine biosynthesis protein ATIC. The names reflect its two enzymatic activities.
Mouse and rat both have an orthologue named Atic. In humans, a mutation in the ATIC gene results in AICA-ribosiduria. Check the datasheet of any product for its validated reactivity before use in a particular species.
Other purine biosynthesis enzymes and insulin receptor signalling targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P31939; product specifications from Assay Genie datasheets.